Vaccination Strategies against Highly Pathogenic Arenaviruses: The Next Steps toward Clinical Trials

English version České info

Vaccination is one of the most valuable weapons against infectious diseases and has led to a significant reduction in mortality and morbidity. However, for most viral hemorrhagic fevers caused by arenaviruses, no prophylactic vaccine is available. This is particularly problematic as these diseases are notoriously difficult to diagnose and treat. Lassa fever is globally the most important of the fevers caused by arenaviruses, potentially affecting millions of people living in endemic areas, particularly in Nigeria. Annually, an estimated 300,000 humans are infected and several thousands succumb to the disease. The successful development of the vaccine “Candid#1” against Junin virus, the causative agent of Argentine hemorrhagic fever, proved that an effective arenavirus vaccine can be developed. Although several promising studies toward the development of a Lassa fever vaccine have been published, no vaccine candidate has been tested in human volunteers or patients. This review summarizes the immunology and other aspects of existing experimental arenavirus vaccine studies, discusses the reasons for the lack of a vaccine, and proposes a plan for overcoming the final hurdles toward clinical trials.

Vyšlo v časopise: Vaccination Strategies against Highly Pathogenic Arenaviruses: The Next Steps toward Clinical Trials. PLoS Pathog 9(4): e32767. doi:10.1371/journal.ppat.1003212
Kategorie: Review
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1003212

Souhrn

Zdroje

1. CharrelRN, de LamballerieX, EmonetS (2008) Phylogeny of the genus Arenavirus. Curr Opin Microbiol 11: 362–368.

2. FischerSA, GrahamMB, KuehnertMJ, KottonCN, SrinivasanA, et al. (2006) Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 354: 2235–2249.

3. LukashevichIS, StelmakhTA, GolubevVP, StchesljenokEP, LemeshkoNN (1984) Ribonucleic acids of Machupo and Lassa viruses. Arch Virol 79: 189–203.

4. AuperinDD, RomanowskiV, GalinskiM, BishopDH (1984) Sequencing studies of pichinde arenavirus S RNA indicate a novel coding strategy, an ambisense viral S RNA. J Virol 52: 897–904.

5. BowenMD, PetersCJ, NicholST (1997) Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts. Mol Phylogenet Evol 8: 301–316.

6. Fisher-HochSP (2005) Lessons from nosocomial viral haemorrhagic fever outbreaks. Br Med Bull 73–74: 123–137.

7. FlatzL, RiegerT, MerklerD, BergthalerA, RegenT, et al. (2010) T cell-dependence of Lassa fever pathogenesis. PLoS Pathog 6: e1000836 doi:10.1371/journal.ppat.1000836.

8. HastieKM, KimberlinCR, ZandonattiMA, MacRaeIJ, SaphireEO (2011) Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3′ to 5′ exonuclease activity essential for immune suppression. Proc Natl Acad Sci U S A 108: 2396–2401.

9. McCormickJB, KingIJ, WebbPA, ScribnerCL, CravenRB, et al. (1986) Lassa fever. Effective therapy with ribavirin. N Engl J Med 314: 20–26.

10. McCormickJB, KingIJ, WebbPA, JohnsonKM, O'SullivanR, et al. (1987) A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis 155: 445–455.

11. MaizteguiJI (1975) Clinical and epidemiological patterns of Argentine haemorrhagic fever. Bull World Health Organ 52: 567–575.

12. MaizteguiJI, McKeeKTJr, Barrera OroJG, HarrisonLH, GibbsPH, et al. (1998) Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis 177: 277–283.

13. AmbrosioA, SaavedraM, MarianiM, GamboaG, MaizaA (2011) Argentine hemorrhagic fever vaccines. Hum Vaccin 7: 694–700.

14. JahrlingPB, PetersCJ (1984) Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. Infect Immun 44: 528–533.

15. JahrlingPB (1983) Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin. J Med Virol 12: 93–102.

16. JahrlingPB, PetersCJ, StephenEL (1984) Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J Infect Dis 149: 420–427.

17. MaizteguiJI, FernandezNJ, de DamilanoAJ (1979) Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 2: 1216–1217.

18. KileyMP, LangeJV, JohnsonKM (1979) Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus. Lancet 2: 738.

19. TaurasoN, ShelokovA (1965) Protection against Junin Virus by Immunization with Live Tacaribe Virus. Proc Soc Exp Biol Med 119: 608–611.

20. CotoCE, ReyE, ParodiAS (1967) Tacaribe virus infection of guinea-pig. Virus distribution, appearance of antibodies and immunity against Junin virus infection. Arch Gesamte Virusforsch 20: 81–86.

21. CotoCE, DamonteEB, CatelloMA, WeissenbacherMC (1980) Protection of guinea pigs inoculated with Tacaribe virus against lethal doses of Junin virus. J Infect Dis 141: 389–393.

22. WeissenbacherMC, CotoCE, CalelloMA, RondinoneSN, DamonteEB, et al. (1982) Cross-protection in nonhuman primates against Argentine hemorrhagic fever. Infect Immun 35: 425–430.

23. VidelaC, CarballalG, RemoriniP, La TorreJ (1989) Formalin inactivated Junin virus: immunogenicity and protection assays. J Med Virol 29: 215–220.

24. LopezN, ScolaroL, RossiC, JacamoR, CandurraN, et al. (2000) Homologous and heterologous glycoproteins induce protection against Junin virus challenge in guinea pigs. J Gen Virol 81: 1273–1281.

25. ter MeulenJ (1999) Lassa fever: implications of T-cell immunity for vaccine development. J Biotechnol 73: 207–212.

26. BoesenA, SundarK, CoicoR (2005) Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2.1 transgenic mice. Clin Diagn Lab Immunol 12: 1223–1230.

27. BottenJ, AlexanderJ, PasquettoV, SidneyJ, BarrowmanP, et al. (2006) Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J Virol 80: 8351–8361.

28. KlenermanP, ZinkernagelRM (1998) Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 394: 482–485.

29. La PostaVJ, AuperinDD, Kamin-LewisR, ColeGA (1993) Cross-protection against lymphocytic choriomeningitis virus mediated by a CD4+ T-cell clone specific for an envelope glycoprotein epitope of Lassa virus. J Virol 67: 3497–3506.

30. OldstoneMB, LewickiH, HomannD, NguyenC, JulienS, et al. (2001) Common antiviral cytotoxic t-lymphocyte epitope for diverse arenaviruses. J Virol 75: 6273–6278.

31. MeulenJ, BaduscheM, SatoguinaJ, StreckerT, LenzO, et al. (2004) Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. Virology 321: 134–143.

32. KotturiMF, BottenJ, SidneyJ, BuiHH, GiancolaL, et al. (2009) A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease. PLoS Pathog 5: e1000695 doi:10.1371/journal.ppat.1000695.

33. BottenJ, WhittonJL, BarrowmanP, SidneyJ, WhitmireJK, et al. (2010) A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans. J Virol 84: 9947–9956.

34. BlattmanJN, WherryEJ, HaSJ, van der MostRG, AhmedR (2009) Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection. J Virol 83: 4386–4394.

35. JohnsonPL, KochinBF, McAfeeMS, StromnesIM, RegoesRR, et al. (2011) Vaccination alters the balance between protective immunity, exhaustion, escape, and death in chronic infections. J Virol 85: 5565–5570.

36. AlbarinoCG, BirdBH, ChakrabartiAK, DoddKA, FlintM, et al. (2011) The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain. J Virol 85: 10404–10408.

37. RiedelS (2005) Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) 18: 21–25.

38. FriersonJG (2010) The yellow fever vaccine: a history. Yale J Biol Med 83: 77–85.

39. MillerJD, van der MostRG, AkondyRS, GlidewellJT, AlbottS, et al. (2008) Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28: 710–722.

40. WalkerDH, JohnsonKM, LangeJV, GardnerJJ, KileyMP, et al. (1982) Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus. J Infect Dis 146: 360–368.

41. LangeJV, MitchellSW, McCormickJB, WalkerDH, EvattBL, et al. (1985) Kinetic study of platelets and fibrinogen in Lassa virus-infected monkeys and early pathologic events in Mopeia virus-infected monkeys. Am J Trop Med Hyg 34: 999–1007.

42. LukashevichIS (1992) Generation of reassortants between African arenaviruses. Virology 188: 600–605.

43. LukashevichIS, PattersonJ, CarrionR, MoshkoffD, TicerA, et al. (2005) A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol 79: 13934–13942.

44. LukashevichIS, CarrionRJr, SalvatoMS, MansfieldK, BraskyK, et al. (2008) Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 26: 5246–5254.

45. MoshkoffDA, SalvatoMS, LukashevichIS (2007) Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses. Virus Genes 34: 169–176.

46. BrancoLM, GroveJN, GeskeFJ, BoisenML, MuncyIJ, et al. (2010) Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol J 7: 279.

47. McCormickJB, MitchellSW, KileyMP, RuoS, Fisher-HochSP (1992) Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys. J Med Virol 37: 1–7.

48. AmannaIJ, RaueHP, SlifkaMK (2012) Development of a new hydrogen peroxide-based vaccine platform. Nat Med 18: 974–979.

49. DjavaniM, YinC, XiaL, LukashevichIS, PauzaCD, et al. (2000) Murine immune responses to mucosally delivered Salmonella expressing Lassa fever virus nucleoprotein. Vaccine 18: 1543–1554.

50. DjavaniM, YinC, LukashevichIS, RodasJ, RaiSK, et al. (2001) Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus. J Hum Virol 4: 103–108.

51. WiktorTJ, MacfarlanRI, ReaganKJ, DietzscholdB, CurtisPJ, et al. (1984) Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci U S A 81: 7194–7198.

52. MackettM, SmithGL, MossB (1982) Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A 79: 7415–7419.

53. ThummelC, TjianR, GrodzickerT (1981) Expression of SV40 T antigen under control of adenovirus promoters. Cell 23: 825–836.

54. FlatzL, HegazyAN, BergthalerA, VerschoorA, ClausC, et al. (2010) Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med 16: 339–345.

55. MartinaBE, van den DoelP, KorakaP, van AmerongenG, SpohnG, et al. (2011) A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus. PLoS One 6: e18995 doi:10.1371/journal.pone.0018995.

56. DondjiB, DeakE, Goldsmith-PestanaK, Perez-JimenezE, EstebanM, et al. (2008) Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania. Eur J Immunol 38: 706–719.

57. CleggJC, LloydG (1987) Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. Lancet 2: 186–188.

58. AuperinDD, EspositoJJ, LangeJV, BauerSP, KnightJ, et al. (1988) Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection. Virus Res 9: 233–248.

59. Fisher-HochSP, HutwagnerL, BrownB, McCormickJB (2000) Effective vaccine for lassa fever. J Virol 74: 6777–6783.

60. GarbuttM, LiebscherR, Wahl-JensenV, JonesS, MollerP, et al. (2004) Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 78: 5458–5465.

61. GeisbertTW, JonesS, FritzEA, ShurtleffAC, GeisbertJB, et al. (2005) Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2: e183 doi:10.1371/journal.pmed.0020183.

62. GuntherS, FeldmannH, GeisbertTW, HensleyLE, RollinPE, et al. (2011) Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 204 Suppl 3: S785–S790.

63. GuyB, GuirakhooF, BarbanV, HiggsS, MonathTP, et al. (2010) Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28: 632–649.

64. JiangX, DaleboutTJ, BredenbeekPJ, CarrionRJr, BraskyK, et al. (2011) Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine 29: 1248–1257.

65. BredenbeekPJ, MolenkampR, SpaanWJ, DeubelV, MarianneauP, et al. (2006) A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 345: 299–304.

66. PushkoP, GeisbertJ, ParkerM, JahrlingP, SmithJ (2001) Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol 75: 11677–11685.

67. RojekJM, SanchezAB, NguyenNT, de la TorreJC, KunzS (2008) Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses. J Virol 82: 7677–7687.

68. HuygenK (2005) Plasmid DNA vaccination. Microbes Infect 7: 932–938.

69. Rodriguez-CarrenoMP, NelsonMS, BottenJ, Smith-NixonK, BuchmeierMJ, et al. (2005) Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology 335: 87–98.

70. McCormickJB, WebbPA, KrebsJW, JohnsonKM, SmithES (1987) A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis 155: 437–444.

71. The World Bank (2012) Gross domestic product ranking table 2011. World development indicators. Washington: The World Bank. Available: http://data.worldbank.org/data-catalog/http://databank.worldbank.org/databank/download/GDP.pdf.

72. OPEC (2013) Market indicators as at end: December 2012. OPEC market indicators. Vienna: Organization of the Petroleum Exporting Countries. Available: http://www.opec.org/opec_web/static_files_project/media/downloads/data_graphs/MI122012.pdf.

73. JohnsonKM, McCormickJB, WebbPA, SmithES, ElliottLH, et al. (1987) Clinical virology of Lassa fever in hospitalized patients. J Infect Dis 155: 456–464.

74. StreetonJA, DesemN, JonesSL (1998) Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection. Int J Tuberc Lung Dis 2: 443–450.

75. ThomasRE, LorenzettiDL, SpraginsW, JacksonD, WilliamsonT (2012) The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. Am J Trop Med Hyg 86: 359–372.

76. BottenJ, WhittonJL, BarrowmanP, SidneyJ, WhitmireJK, et al. (2007) HLA-A2-restricted protection against lethal lymphocytic choriomeningitis. J Virol 81: 2307–2317.

77. KotturiMF, SwannJA, PetersB, ArlehamnCL, SidneyJ, et al. (2011) Human CD8(+) and CD4(+) T cell memory to lymphocytic choriomeningitis virus infection. J Virol 85: 11770–11780.

78. KotturiMF, BottenJ, MaybenoM, SidneyJ, GlennJ, et al. (2010) Polyfunctional CD4+ T cell responses to a set of pathogenic arenaviruses provide broad population coverage. Immunome Res 6: 4.

79. ter MeulenJ, BaduscheM, KuhntK, DoetzeA, SatoguinaJ, et al. (2000) Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J Virol 74: 2186–2192.